GSK opens first-in-Singapore high potency manufacturing and testing facility for next generation cancer treatments

• S$44m investment in the new high potency manufacturing facility and laboratory further strengthens Jurong site capabilities to launch new products more quickly 
• Facility will manufacture a key ingredient for antibody drug conjugates (ADCs)

GSK plc today announced the opening of a new, S$44 million high potency facility (HPF) in its strategic New Product Introduction site in Jurong, Singapore. The opening of the facility was officiated by Guest-of-Honour, Singapore’s Minister for Health, Mr. Ong Ye Kung, and Mr. Regis Simard, GSK’s President, Global Supply Chain. The HPF will be used to produce a key ingredient, which is a cytotoxic component, in antibody drug conjugates (ADCs) to treat cancer. Today’s event also marks 40 years since the Jurong site opened in Singapore in 1982.

This facility is the first in Singapore capable of producing highly potent cytotoxic ingredients in ADCs, for breakthrough immunotherapy cancer treatments. It is equipped with advanced features such as specialised equipment, automated operations, exceptional containment capabilities and strict cross-contamination control. It is built to facilitate complete in-house manufacturing to safeguard supply chain processes, quality control and timeliness of delivery. It also features leadingedge capabilities to handle high potency manufacturing under a highly safe and controlled environment.

With the addition of the HPF, GSK has further strengthened the Jurong site capabilities as a New Product Introduction (NPI) site to launch new products more quickly. The capability to produce high potency components at scale helps to meet the increasing demand for oncology treatments around the world.